
Amgen says its Humira (adalimumab) biosimilar candidate ABP 501 proved its clinical equivalence to Abbvie’s blockbuster drug in a head-to-head …
Takeda UK is bolstering its Medical and Human Resources functions as Takeda continues to develop its expertise in the Specialty …

The FDA has approved AstraZeneca’s new lung cancer drug Tagrisso, in a record two and half years from development, under …

Perrigo has rejected Mylan’s hostile $26 billion bid after a 60% majority of shareholders were unconvinced by the terms by …

Gilead’s Harvoni has been approved by the FDA for expanded use in patients with genotypes 4, 5 and 6 chronic …

Dr Mene Pangalos, executive vice president of the IMED Biotech Unit at AstraZeneca UK, has accepted two prestigious appointments that …

The American Heart Association and Google Life Sciences have announced a joint research collaboration to bring ‘unconventional thinking’ to the …

Seven pharma companies have been rated among the world’s 100 most innovative companies, according to Thomson Reuters.The business intelligence firm …

Roche has announced plans to restructure its manufacturing network for small molecules, in a move that will see it mothball …

Boehringer Ingelheim has launched its new research and development strategy, committing €11 billion to R&D over the next five years. …

Pharma’s new-found willingness to embrace all aspects of the digital age, and use it both to its advantage and that …

New data reveals that while antibiotic prescriptions have fallen across England in the last three years, struggling GP practices in …

The Scottish Medicines Consortium (SMC) has given the go-ahead for the use of several drugs on the NHS in Scotland. …

Having presented positive late-stage results for a new formulation of its inflammatory drug Benlysta, GSK says it will file supplementary …

German pharma group Merck has earned a 7% bump in its sales, and a 10% boost in earnings before deductions, …

International medical aid charity Médecins Sans Frontières/Doctors Without Borders (MSF) is taking action against GlaxoSmithKline and Pfizer, calling on the …

LEO Pharma, the speciality dermatology firm, is looking to expand its presence in the therapy area by buying Astellas’ portfolio …

Astellas Pharma has agreed to buy Ocata, a firm specialising in cloning and embryonic stem cell therapies, for $379 million. …

The FDA has approved the skin cancer drug Cotellic for certain forms of melanoma in combination with another Roche cancer …

A shortage of skilled professionals threatens to undermine research and development of new medicines in the UK and prevent growth …